Antimanic Agents - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Enhancing multiyear guideline concordance for bipolar disorder through collaborative care.

29 Sep 2009 OBJECTIVE: Implementation of evidence-based care for serious mental illnesses such as bipolar disorder has been suboptimal. Improving and sustaining concordance with clinical practice guidelines has been a cornerstone of efforts to enhance ... Read more...

An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential.

30 Aug 2009 OBJECTIVES: Progress toward understanding the neurobiological and genetic underpinnings of bipolar disorder has been limited by the scarcity of potential biological markers that predict its occurrence. A measure of the integrity of brain inhibitory ... Read more...

The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.

30 Aug 2009 OBJECTIVES: Safety monitoring is an important aspect of bipolar disorder treatment, as mood-stabilising medications have potentially serious side effects, some of which may also aggravate existing medical comorbidities. This paper sets out the ... Read more...

Latest indexed articles for 'Antimanic Agents - Therapeutic use'

These are the very latest articles for this heading:

• Closing the gap between guidelines for bipolar disorder treatment and clinical practice. 30 Oct 2009
• Lithium-induced kidney problems. Serious problems are unusual, but monitoring is key. 29 Sep 2009
• Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. 29 Sep 2009
• Combination treatment with quetiapine in bipolar disorder patients. 29 Sep 2009
• Maintenance treatment for patients with bipolar disorder. 29 Sep 2009
• An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. 30 Aug 2009
• The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. 30 Aug 2009
• A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. 30 Aug 2009
• Carbamazepine-induced hyperammonemia. 13 Aug 2009
• Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. 9 Aug 2009
• Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. 30 Jul 2009
• The failure to know what isn't known: negative publication bias with lamotrigine and a glimpse inside peer review. 30 Jul 2009
• Treatment-refractory bipolar disorder: classification to aid in clinical management. 30 Jul 2009
• No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. 29 Jul 2009
• Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. 8 Jul 2009
• Valproate preparations for agitation in dementia. 6 Jul 2009
• Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. 5 Jul 2009
• A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial. 29 Jun 2009
• [Inadequate vasopressin secretion and valproate] 29 Jun 2009
• Bariatric surgery in patients with bipolar disorder: an emerging issue. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Antimanic Agents'

Definition: Agents that are used to treat bipolar disorders or mania associated with other affective disorders.

Registry Number: 0

Descriptor UI: D018692

Alternative terms: Antimanic Agents; Agents, Antimanic; Antimanic Drugs; Drugs, Antimanic; Antimanics;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.277.950.025; D27.505.954.427.210.950.025; D27.505.954.427.700.872.025;

History Note: 95

Technical Notes: tranquilizing agents; consider also BIPOLAR DISORDER /drug ther